Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma

Journal of Urology

Volumn 184, Issue 5, 2010, Pages 2143-2149

  Ishimaru, Tatsuto ^a   Lau, Jasmine ^a   Jackson, Amy L ^c   Modiano, Jaime F ^d   Weiss, Robert H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apoptosis; Carcinoma, renal cell; Cyclin dependent kinases; Kidney; Roscovitine

Indexed keywords

CYCLIN DEPENDENT KINASE; NUTLIN 3; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; ROSCOVITINE; VON HIPPEL LINDAU PROTEIN; X LINKED INHIBITOR OF APOPTOSIS; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; KIDNEY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

APOPTOSIS; CARCINOMA, RENAL CELL; CYCLIN-DEPENDENT KINASES; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PURINES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957846979     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.06.088     Document Type: Article

References (24)

1. R.H. Weiss, and P.Y. Lin Kidney cancer: identification of novel targets for therapy Kidney Int 69 2006 224
2. S.H. Park, J.Y. Park, and R.H. Weiss Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53 J Urol 180 2008 352
3. H.M. Coley, C.F. Shotton, and M.I. Kokkinos The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines Gynecol Oncol 105 2007 462
4. C.F. Cheok, A. Dey, and D.P. Lane Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination Mol Cancer Res 5 2007 1133
5. M.V. Appleyard, M.A. O'Neill, and K.E. Murray Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model Int J Cancer 124 2009 465
6. S.H. Park, X. Wang, and R. Liu High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers Cancer Biol Ther 7 2008 2015
7. S. Bach, M. Knockaert, and J. Reinhardt Roscovitine targets, protein kinases and pyridoxal kinase J Biol Chem 280 2005 31208
8. P.M. Fischer, and A. Gianella-Borradori CDK inhibitors in clinical development for the treatment of cancer Expert Opin Investig Drugs 12 2003 955
9. E.H. Kim, S.U. Kim, and D.Y. Shin Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP Oncogene 23 2004 446
10. O.M. Tirado, S. Mateo-Lozano, and V. Notario Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo Cancer Res 65 2005 9320
11. S.R. Whittaker, M.I. Walton, and M.D. Garrett The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway Cancer Res 64 2004 262
12. M. Paprskarova, V. Krystof, and R. Jorda Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine J Cell Biochem 107 2009 428
13. P.Y. Lin, S.P. Fosmire, and S.H. Park Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance Mol Cancer 6 2007 16
14. Waf1/Cip1 is an assembly factor required for PDGF-induced vascular smooth muscle cell proliferation J Biol Chem 275 2000 10285
15. F.I. Raynaud, S.R. Whittaker, and P.M. Fischer In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202 Clin Cancer Res 11 2005 4875
16. Y. Gu, J. Rosenblatt, and D.O. Morgan Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15 EMBO J 11 1992 3995
17. J. Fu, H.G. Yoon, and J. Qin Regulation of P-TEFb elongation complex activity by CDK9 acetylation Mol Cell Biol 27 2007 4641
18. L. Meijer, A. Borgne, and O. Mulner Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5 Eur J Biochem 243 1997 527
19. W. Lu, L. Chen, and Y. Peng Activation of p53 by roscovitine-mediated suppression of MDM2 expression Oncogene 20 2001 3206
20. A.R. Schoenfeld, T. Parris, and A. Eisenberger The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis Oncogene 19 2000 5851
21. H. Miyake, I. Hara, and K. Gohji p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line Int J Oncol 12 1998 469
22. J.S. Roe, H. Kim, and S.M. Lee p53 stabilization and transactivation by a von Hippel-Lindau protein Mol Cell 22 2006 395
23. R.H. Weiss p21Waf1/Cip1 as a therapeutic target in breast and other cancers Cancer Cell 4 2003 425
24. A.L. Gartel, and A.L. Tyner The role of the cyclin-dependent kinase inhibitor p21 in apoptosis Mol Cancer Ther 1 2002 639